168 related articles for article (PubMed ID: 25886699)
1. Orbital MRI Pre- and Post-Vemurafenib Therapy for Erdheim-Chester Disease.
Grumbine FL; Aderman C; Vagefi MR; Kersten RC
Ophthalmic Plast Reconstr Surg; 2015; 31(6):e169. PubMed ID: 25886699
[No Abstract] [Full Text] [Related]
2. Vemurafenib (BRAF Inhibitor) Therapy for Orbital Erdheim-Chester Disease.
Gupta A; Yeganeh A; Rootman D; Goldberg R
Ophthalmic Plast Reconstr Surg; 2017; 33(6):e138-e139. PubMed ID: 28099231
[TBL] [Abstract][Full Text] [Related]
3. A cytologic diagnosis of BRAF
Chasseur P; Kyriakopoulou M; Vokaer B; Beukinga I; Casado Arroyo R; Cogan E; Couturier B
Acta Clin Belg; 2017 Oct; 72(5):369-371. PubMed ID: 28222655
[TBL] [Abstract][Full Text] [Related]
4. Erdheim-Chester's disease of the heart: a diagnostic conundrum and collision with the same mass in the orbit.
Bogáts G; Piros G; Tiszlavicz L; Iványi B; Sasi V; Csepregil L; Simon J; Babik B; Csillik A; Kardos L; Palkó A; Matin K; Hanzély Z; Korányi K; Nyáry I; Végh M; Kolozsvári L; Kahán Z; Bajcsay A; Tóth A; Balázs G; Simor T; Pávics L; Palotás A
Heart Surg Forum; 2006; 9(1):E549-54. PubMed ID: 16403713
[TBL] [Abstract][Full Text] [Related]
5. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Rheum Dis Clin North Am; 2013 May; 39(2):299-311. PubMed ID: 23597965
[TBL] [Abstract][Full Text] [Related]
6. Saving orphans: BRAF targeting of histiocytosis.
Heaney ML
Blood; 2013 Feb; 121(9):1487-8. PubMed ID: 23449613
[TBL] [Abstract][Full Text] [Related]
7. Erdheim-Chester disease.
Campochiaro C; Tomelleri A; Cavalli G; Berti A; Dagna L
Eur J Intern Med; 2015 May; 26(4):223-9. PubMed ID: 25865950
[TBL] [Abstract][Full Text] [Related]
8. Low-dose vemurafenib monotherapy in
Ruan GJ; Hazim A; Abeykoon JP; Scheckel C; Vassallo R; Ryu JH; Tobin WO; Koster MJ; Bennani NN; Rech KL; Young JR; Shah MV; Goyal G; Go RS
Leuk Lymphoma; 2020 Nov; 61(11):2733-2737. PubMed ID: 32608295
[No Abstract] [Full Text] [Related]
9. Targeted therapies in 54 patients with Erdheim-Chester disease, including follow-up after interruption (the LOVE study).
Cohen Aubart F; Emile JF; Carrat F; Charlotte F; Benameur N; Donadieu J; Maksud P; Idbaih A; Barete S; Hoang-Xuan K; Amoura Z; Haroche J
Blood; 2017 Sep; 130(11):1377-1380. PubMed ID: 28667012
[No Abstract] [Full Text] [Related]
10. Marked efficacy of vemurafenib in suprasellar Erdheim-Chester disease.
Cohen-Aubart F; Emile JF; Maksud P; Galanaud D; Idbaih A; Chauvet D; Amar Y; Benameur N; Amoura Z; Haroche J
Neurology; 2014 Sep; 83(14):1294-6. PubMed ID: 25171932
[No Abstract] [Full Text] [Related]
11. The histiocytosis Erdheim-Chester disease is an inflammatory myeloid neoplasm.
Haroche J; Cohen-Aubart F; Charlotte F; Maksud P; Grenier PA; Cluzel P; Mathian A; Emile JF; Amoura Z
Expert Rev Clin Immunol; 2015; 11(9):1033-42. PubMed ID: 26197238
[TBL] [Abstract][Full Text] [Related]
12. Erdheim Chester disease with appendicular skeletal, renal and pleural involvement responding to Zelboraf (BRAF inhibitor) treatment: case report.
Borys D; Nystrom L; Song A; Lomasney LM
Skeletal Radiol; 2016 Oct; 45(10):1397-402. PubMed ID: 27423231
[TBL] [Abstract][Full Text] [Related]
13. [Erdheim-Chester disease].
Mazor RD; Shoenfeld Y
Harefuah; 2014 Jul; 153(7):389-91, 434, 433. PubMed ID: 25189027
[TBL] [Abstract][Full Text] [Related]
14. Dramatic efficacy of vemurafenib in both multisystemic and refractory Erdheim-Chester disease and Langerhans cell histiocytosis harboring the BRAF V600E mutation.
Haroche J; Cohen-Aubart F; Emile JF; Arnaud L; Maksud P; Charlotte F; Cluzel P; Drier A; Hervier B; Benameur N; Besnard S; Donadieu J; Amoura Z
Blood; 2013 Feb; 121(9):1495-500. PubMed ID: 23258922
[TBL] [Abstract][Full Text] [Related]
15. Erdheim-Chester disease.
Haroche J; Arnaud L; Cohen-Aubart F; Hervier B; Charlotte F; Emile JF; Amoura Z
Curr Rheumatol Rep; 2014 Apr; 16(4):412. PubMed ID: 24532298
[TBL] [Abstract][Full Text] [Related]
16. [Orbit xanthogranulomatosis. Erdheim-Chester disease].
Rozas Reyes P; Señaris González A; González Rodríguez CM
Arch Soc Esp Oftalmol; 2004 Oct; 79(10):515-8. PubMed ID: 15523574
[TBL] [Abstract][Full Text] [Related]
17. [Erdheim-Chester disease presenting with bilateral orbital involvement: Report of three cases].
Kiratli H; Koç I; Söylemezoğlu F
J Fr Ophtalmol; 2020 Nov; 43(9):851-857. PubMed ID: 32829941
[TBL] [Abstract][Full Text] [Related]
18. Superior efficacy and tolerance of reduced doses of vemurafenib plus anakinra in Erdheim-Chester disease: Towards the paradigm of combined targeting and immune therapies.
Franconieri F; Martin-Silva N; de Boysson H; Galateau-Salle F; Emile JF; Bienvenu B; Aouba A
Acta Oncol; 2016 Jul; 55(7):930-2. PubMed ID: 27031008
[No Abstract] [Full Text] [Related]
19. Orbital involvement in Erdheim-Chester disease.
Lau WW; Chan E; Chan CW
Hong Kong Med J; 2007 Jun; 13(3):238-40. PubMed ID: 17548915
[TBL] [Abstract][Full Text] [Related]
20. Excellent response of intramedullary Erdheim-Chester disease to vemurafenib: a case report.
Tzoulis C; Schwarzlmüller T; Gjerde IO; Søfteland E; Neckelmann G; Biermann M; Haroche J; Straume O; Vintermyr OK
BMC Res Notes; 2015 Apr; 8():171. PubMed ID: 25926131
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
